Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-06-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.


Scope

  • This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016
  • Assessment of current and future opportunities and threats in the MS market across the 7MMs
  • Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs
  • Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market


    • Report Highlights
    Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. Datamonitor believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.

    In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxonelaunched in 1997Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.

    There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idec's strategy to market two or more products and show commitment to the MS community through long-term franchise investment.


    Reasons to Purchase

  • Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands
  • Quantify the future size of the MS market, in terms of volume and value, in each of the 7MM
  • Identify key lifecycle management strategies that can ensure growth in the competitive MS market

    • Table of Contents

    Other users found this report page using the following search terms: multiple sclerosis neurodegenerative disease sclerosis multiple market rebif patent date sales avonex fingolimod launch

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.